消除结构性障碍:无限制获取对HIV感染者丙肝治疗 uptake 的影响
该研究利用加拿大HIV-HCV合并感染队列数据,采用双重差分法评估取消纤维化分期限制对HIV感染者HCV治疗启动率的影响。边缘化人群和脱离照护者更可能仍未治疗。
要点
- 取消纤维化分期限制后HCV治疗启动率立即增加1.8倍,但未持续。
- 注射吸毒者中治疗启动增加更明显,调整后发生率比3.6。
- 边缘化人群和脱离照护者更可能仍未接受HCV治疗。
核心结论
- 取消纤维化限制后HCV治疗启动率几乎立即翻倍,但该治疗率未能持续。
- 为实现WHO消除目标,需最小化结构性障碍并采取定制干预措施以覆盖所有脆弱人群。
研究设计与样本
- 利用加拿大HIV-HCV合并感染队列数据,采用双重差分法评估取消纤维化分期限制的影响。
- 使用负二项回归和广义估计方程评估治疗启动率变化,并用修正泊松回归识别仍未治疗者的特征。
- 2010-2018年间,1130名合格参与者中共有585次HCV治疗启动。
主要发现
- 取消纤维化分期限制后,控制时间不变差异和长期趋势,DAA治疗启动增加1.8倍(95%CI 1.3-2.4)。
- 在注射吸毒者中影响更强,调整后发生率比为3.6(95%CI 1.8-7.4)。
- 边缘化参与者(注射吸毒者和原住民)及脱离照护者更可能保持HCV RNA阳性。
临床怎么用
- 取消纤维化分期限制可快速提高HIV合并HCV感染者的治疗启动率。
- 需针对注射吸毒者、原住民和脱离照护者等脆弱人群采取定制干预以维持治疗覆盖。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High costs of direct-acting antivirals (DAAs) have led health-care insurers to limit access worldwide. Using a natural experiment, we evaluated the impact of removing fibrosis stage restrictions on hepatitis C (HCV) treatment initiation rates among people living with human immunodeficiency virus (HIV), and then examined who was left to be treated. METHODS: Using data from the Canadian HIV-HCV Coinfection Cohort, we applied a difference-in-differences approach. Changes in treatment initiation rates following the removal of fibrosis stage restrictions were assessed using a negative binomial regression with generalized estimating equations. The policy change was then specifically assessed among people who inject drugs (PWID). We then identified the characteristics of participants who remained to be treated using a modified Poisson regression. RESULTS: Between 2010-2018, there were a total of 585 HCV initiations among 1130 eligible participants. After removing fibrosis stage restrictions, DAA initiations increased by 1.8-fold (95% confidence interval [CI] 1.3-2.4) controlling for time-invariant differences and secular trends. Among PWID the impact appeared even stronger, with an adjusted incidence rate ratio of 3.6 (95% CI 1.8-7.4). However, this increased treatment uptake was not sustained. At 1 year following universal access, treatment rates declined to 0.8 (95% CI .5-1.1). Marginalized participants (PWID and those of indigenous ethnicity) and those disengaged from care were more likely to remain HCV RNA positive. CONCLUSIONS: After the removal of fibrosis restrictions, HCV treatment initiations nearly doubled immediately, but this treatment rate was not sustained. To meet the World Health Organization elimination targets, the minimization of structural barriers and adoption of tailored interventions are needed to engage and treat all vulnerable populations.
引用
- Saeed S, Strumpf E, Moodie EEM, et al. Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus. Clin Infect Dis. 2020. PMID: 31504327. doi:10.1093/cid/ciz833
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。